TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8558201
Drug: Busulfan (BU)
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan (BU) 7 mg/kg, Cyclophosphamide (CY) 50 mg/kg, Total-body irradiation (TBI) 12 Gy
Study: 8558201
Drug: Conventional Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Cyclophosphamide (CY) 120 mg/kg and TBI (historical control)
Study: 6126901
Drug: Chlorpromazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (50 mg)
Study: 6337363
Drug: Objective laboratory
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Objective laboratory tests indicating good prognosis (total serum protein >= 6 g%, SGOT <= 40 mU/ml, total serum bilirubin <= 0.6 mg%)
Study: 27871576
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (effect site concentration of 4 ng/mL)
Study: 27871576
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (effect site concentration of 1 ng/mL)
Study: 27871576
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen (800 mg)
Study: 20361466
Drug: Rituximab added
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab added to standard chemotherapy regimens
Study: 20361466
Drug: Monoclonal antibody-based
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody-based therapy
Study: 15755830
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (100 g containing approximately 500 mg polyphenols)
Study: 3933604
Drug: Low-dose 15
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 15 MeV neutrons (LDN)
Study: 3933604
Drug: High-dose 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 15 MeV neutrons (HDN)
Study: 3933604
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of photon and neutron therapy
Study: 8256468
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antioxidant therapy)
Study: 24817601
Drug: Oral imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral imatinib at doses ranging between 300 and 800 mg
Study: 22335737
Drug: Semuloparin 20
Normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semuloparin 20 mg once daily
Study: 17401042
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with lower anxiety
Study: 17401042
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with higher anxiety
Study: 10840425
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (neodymium:YAG noncontact visual prostate ablation)
Study: 9356557
Drug: Personal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal therapy among patients living with family
Study: 9356557
Drug: Personal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal therapy among patients living independently
Study: 9356557
Drug: Family and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family and supportive therapies among patients living with family
Study: 9356557
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy among patients living independently
Study: 8457085
Drug: Indobufen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (oral antiplatelet agent)
Study: 26646803
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (G2) received 1 L of PEG in the day before SBCE and 1 L of PEG in the morning before SBCE (time between PEG and SBCE=4 h)
Study: 26646803
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (G1) received 2 L of PEG in the day before SBCE (time between PEG and SBCE=10 h)
Study: 24160904
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser treatment plus standard wound care
Study: 24160904
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment plus standard wound care
Study: 18654867
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg (after dosage increase)
Study: 18654867
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg with compliance enhancement tools
Study: 14501815
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate (GnRH agonist) for 3 months
Study: 10898414
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation (gamma and beta emitters), maximum dose to the vessel wall was 30 to 55 Gy, followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Study: 10898414
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (no radiation), followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Study: 9372677
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg/kg in 250 ml D5W
Study: 9372677
Drug: Placebo (CON)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (CON) 250 ml D5W
Study: 2427393
Drug: Oral urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral urokinase
Study: 30613009
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment combined with traditional Chinese medicine retention enema (Control)
Study: 27418333
Drug: Low-concentration contrast
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration contrast agents (270 and 320 mg iodine/ml)
Study: 27418333
Drug: High-concentration contrast
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration contrast agent (370 mg iodine/ml)
Study: 22916818
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g isolated yellow pea protein (P20)
Study: 22916818
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g isolated yellow pea protein (P10)
Study: 22916818
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g isolated yellow pea fibre (F10)
Study: 22916818
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g isolated yellow pea fibre (F20)
Study: 18678301
Drug: CP-778,875 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-778,875 2 mg/day
Study: 18678301
Drug: CP-778,875 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-778,875 0.5, 2, or 6 mg/day
Study: 18678301
Drug: CP-778,875 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-778,875 6 mg/day
Study: 12027463
Drug: Immune modulation
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune modulation therapy (IMT) - 10 ml of citrated autologous blood administered by intra-muscular injection after exposure to UV light and oxidisation, 6 injections over 3 weeks followed by 3 weeks rest, with 2-4 courses depending on response.
Study: 12027463
Drug: Immune modulation
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune modulation therapy (IMT) - subgroup analysis for short distance claudicants
Study: 15613167
Drug: Butorphanol nasal
Normalized name: butorphanol nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol nasal spray 1 mg followed by optional second 1 mg dose
Study: 15613167
Drug: Fiorinal with
Normalized name: Fiorinal with Codeine
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fiorinal with Codeine (one capsule containing butalbital 50 mg, caffeine 40 mg, aspirin 325 mg, and codeine phosphate 30 mg)
Study: 27008577
Drug: Topical ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ropivacaine (injected at three portal sites and atomized in the abdominal cavity)
Study: 27008577
Drug: Topical ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ropivacaine
Study: 22099039
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (500 mg twice a day)
Study: 15683891
Drug: Combination neomycin‐polymyxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination neomycin‐polymyxin B‐hydrocortisone
Study: 7328569
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of levamisole on 3 consecutive days
Study: 7328569
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of levamisole once weekly
Study: 20053398
Drug: 200mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg of oral mifepristone followed by 400 microg of oral misoprostol (group 1)
Study: 20053398
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg of sublingual misoprostol repeated every 4 hours for up to a maximum of 3 doses (group 2)
Study: 16468528
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg preoperatively
Study: 15211533
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (5000 lux for 50 minutes per day for 5 days)
Study: 4034296
Drug: Subcutaneous growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous growth hormone therapy
Study: 4034296
Drug: Intramuscular growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular growth hormone therapy
Study: 29996928
Drug: Sequential engagement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential engagement strategy starting with nurses then involving doctors
Study: 27094945
Drug: PF-06743649 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06743649 (40 mg dose)
Study: 22891748
Drug: Azithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (30 mg/kg once a week)
Study: 18723857
Drug: Morphine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (100 microg kg(‐1) loading dose; 10-30 microg kg(‐1) h(‐1) infusion for 14 days)
Study: 12658028
Drug: Guanabenz (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz (2 mg/day)
Study: 12658028
Drug: Guanabenz (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz (4 mg/day)
Study: 9444445
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug treatment (Control)
Study: 29032449
Drug: Self-Help Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Help Cognitive Behavioral Treatment (SHCBT)
Study: 27119581
Drug: Softgel capsule
Normalized name: Renal Softgel Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel capsule (diclofenac potassium 50 mg)
Study: 27119581
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (diclofenac potassium 50 mg)
Study: 27119581
Drug: Tablet (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (diclofenac potassium 50 mg)
Study: 27119581
Drug: Softgel capsule
Normalized name: Renal Softgel Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel capsule vs Oral solution
Study: 27119581
Drug: Softgel capsule
Normalized name: Renal Softgel Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel capsule vs Tablet
Study: 27119581
Drug: Softgel capsule
Normalized name: Renal Softgel Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel capsule
Study: 22367274
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy by a trained nurse for 10 weeks
Study: 20139154
Drug: i.p. chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.p. chemotherapy
Study: 15839930
Drug: ESWL (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL (second treatment)
Study: 6865429
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol doses
Study: 6865429
Drug: High alcohol
Normalized name: High alcohol lager
Approvals — FDA: no, EMA: no, PMDA: no
Description: High alcohol doses
Study: 22865490
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tramadol and 100 mg dexketoprofen trometamol
Study: 22865490
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tramadol with 100 ml 0.9% normal saline
Study: 19937984
Drug: Spinal saddle
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal saddle block (1.0 ml 0.5 per cent hyperbaric bupivacaine)
Study: 19937984
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol and fentanyl
Study: 15800328
Drug: Parenteral hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral hydration with 1,000 mL administered over 4 hours for 2 days
Study: 15800328
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 100 mL normal saline administered over 4 hours for 2 days
Study: 22459230
Drug: Parenteral hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral hydration
Study: 11921156
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg per day for the first four weeks, then 10 mg per day thereafter)
Study: 334478
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg flurbiprofen daily
Study: 26142337
Drug: FRG +
Normalized name: Fampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FRG + GP chemotherapy
Study: 16571285
Drug: GP chemotherapy
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP chemotherapy alone
Study: 15365928
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural block with 7 mL of lidocaine 2% and repeated doses of 5 mL of lidocaine 2% during the operation.
Study: 15365928
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository (NSAID)
Study: 11136300
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil 80 mg
Study: 1333267
Drug: Intravenous 6-thioguanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 6-thioguanine (6-TG) at 55 mg/m2 administered over 30 minutes for 5 consecutive days, repeated every 35 days.
Study: 1333267
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2 on day 1), 5-fluorouracil (800 mg/m2/day as continuous intravenous infusion over 5 days), and oral leucovorin (100 mg every 4 hours during the entire duration of cisplatin and 5-FU infusions), repeated every three weeks.
Study: 30420289
Drug: LCB01-0371 400-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 400-1600 mg BID for 7 days
Study: 30420289
Drug: LCB01-0371 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 800 mg single oral dose
Study: 30420289
Drug: LCB01-0371 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 400 mg tablet
Study: 23040973
Drug: Long-term growth
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term growth hormone (GH) therapy
Study: 17954694
Drug: Intravenous tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tigecycline (100 mg loading dose followed by 50 mg every 12 h or 50 mg loading dose followed by 25 mg every 12 h)
Study: 6365803
Drug: Penbutolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (40 mg daily)
Study: 31898647
Drug: PEG‐LD 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐LD 25 mg/m2 and docetaxel 50 mg/m2
Study: 31898647
Drug: PEG‐LD 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐LD 30 mg/m2 and docetaxel 50 mg/m2
Study: 31898647
Drug: PEG‐LD 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐LD 30 mg/m2 and docetaxel 60 mg/m2
Study: 27703344
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (HD) of Fluticasone 1,000 μg/day
Study: 12868184
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg once daily for 30 days
Study: 12868184
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg once daily for 30 days
Study: 10372724
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion (1.1 mg calcium gluconate/cc in 5% dextrose at a rate of 4 cc/kg x h) (n = 7)
Study: 10372724
Drug: Human PTH-(1-34)
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Human PTH-(1-34) infusion (0.55 U/kg x h) (n = 9)
Study: 8501265
Drug: Baclofen as
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen as protective therapy
Study: 3123603
Drug: L‐deprenyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐deprenyl
Study: 29752998
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein group (HP) - 35 g of protein after training sessions
Study: 29752998
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein group (LP) - 35 g of placebo after training sessions
Study: 22691263
Drug: NOP‐47 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOP‐47 (5 g)
Study: 7925334
Drug: sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 2 micrograms ml‐1 (5 micrograms h‐1) in 0.167% bupivacaine
Study: 7925334
Drug: sufentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 4 micrograms ml‐1 (10 micrograms h‐1) in 0.167% bupivacaine
Study: 7925334
Drug: sufentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 4 micrograms ml‐1 (10 micrograms h‐1) in normal saline
Study: 1190685
Drug: Postoperative intraperitoneal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intraperitoneal lavage with antibiotics
Study: 1190685
Drug: Postoperative drainage
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative drainage without lavage, systemic antibiotics
Study: 27168463
Drug: Flurbiprofen (FP)
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen (FP) patch
Study: 23233136
Drug: lidocaine +
Normalized name: Lidocaine + Menthol Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine + metoclopramide (10 mg)
Study: 23233136
Drug: lidocaine +
Normalized name: Lidocaine + Menthol Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine + ketamine (5 mg)
Study: 23233136
Drug: lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine (20 mg)
Study: 3881242
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily
Study: 9100593
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IGF-I (rhIGF-I) therapy (80 micrograms.kg.day)
Study: 8112546
Drug: Upper gastrointestinal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper gastrointestinal endoscopy with sedation using i.v. midazolam at a dosage of 0.05 mg/kg
Study: 3595668
Drug: Adriamycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (20 mg/week)
Study: 27225729
Drug: Dairy yogurt
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy yogurt supplemented with rhamnogalacturonan (RG) - 150 mL daily containing 50 mg of probiotics and 100 mg of hallabong peel polysaccharide (60% RG) for 8 weeks
Study: 27225729
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group - same product without hallabong peel supplement for 8 weeks
Study: 21748368
Drug: 6% CHO-E
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% CHO-E solution
Study: 21748368
Drug: 2% CHO-E
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHO-E solution
Study: 21748368
Drug: 10% CHO-E
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% CHO-E solution
Study: 12422579
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA)
Study: 12422579
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM)
Study: 12422579
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA)